Wyeth said on Friday that U.S. regulators addressed an approvable letter seeking for more information about its osteoporosis drug, delaying the approval of the treatment.

The U.S. Food and Drug Administration urged the group to present further analysis and identified specific questions regarding reporting and data compilation of the osteoporosis drug bazedoxifene, a treatment of postmenopausal osteoporosis.

Wyeth received two more approvable letters from the FDA in 2007, which notify that the FDA is likely to approve a product application after the company completes specific conditions.

Wyeth will reply to the letter by the end of this year, the company said in a statement.

Shares of Wyeth were down 0.73 percent down at $43.56 in afternoon trading of the New York Stock Exchange..